Company profile: Immunicum
1.1 - Company Overview
Company description
- Provider of clinical phase II cancer immunotherapies, including therapeutic cancer vaccines and T-cell expansion methods rooted in transplantation immunology. Offerings include Vididencel, a maintenance therapy for measurable residual disease in AML and ovarian cancer; Ilixadencel, an intratumoral immune primer of pro-inflammatory donor dendritic cells for combination treatment of hard-to-treat solid tumors; and a preclinical memory NK-cell expansion platform.
Products and services
- Ilixadencel: An intratumoral immune primer comprising pro-inflammatory dendritic cells from healthy donors, used in combination regimens for hard-to-treat solid tumors such as soft tissue sarcomas
- Vididencel: A maintenance-stage therapy for measurable residual disease in AML and ovarian cancer, aiming to induce immune responses against tumor antigens
- NK cell platform: A preclinical method and platform for expansion of memory NK cells for therapeutic purposes and applications
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Immunicum
Amal Therapeutics
HQ: Switzerland
Website
- Description: Provider of proprietary oncology immunisation technology and therapeutic cancer vaccines, built on its KISIMA platform that delivers multiple antigens in a single vaccine. Offerings include ATP128, a clinical-stage therapeutic vaccine targeting metastatic colorectal cancer, and collaboration opportunities in immuno-oncology.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Amal Therapeutics company profile →
Kinnate Biopharma
HQ: United States
Website
- Description: Provider of precision oncology therapeutics for genomically-defined cancers, leveraging structure-based drug discovery and translational research. Pipeline includes exarafenib (KIN-2787), a pan-RAF inhibitor for BRAF/NRAS-driven tumors; KIN-3248 targeting FGFR2/3 alterations in intrahepatic cholangiocarcinoma and urothelial carcinoma; KIN-8741, a selective c-MET inhibitor; and a potentially brain-penetrant CDK4 inhibitor for adult solid tumors.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Kinnate Biopharma company profile →
Lightpoint Medical
HQ: United Kingdom
Website
- Description: Provider of intraoperative imaging technology for real-time cancer detection during surgery, including Cerenkov Luminescence Imaging (CLI) to reduce recurrence and reoperation; offers SENSEI®, a miniature gamma probe for minimally-invasive and robot-assisted procedures to detect radiation and guide surgeons.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Lightpoint Medical company profile →
Suros Surgical
HQ: United States
Website
- Description: Provider of award-winning, Indiana-based medical devices enabling minimally invasive tissue excision and biopsy across multiple surgical specialties, built on patented surgical platform technology.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Suros Surgical company profile →
Exact Imaging
HQ: Canada
Website
- Description: Provider of 29 MHz micro-ultrasound imaging for real-time targeted prostate biopsies via the ExactVu system, offering high-resolution visualization and enhancements like ExactVu Micro Doppler. Solutions include PRI-MUS protocol for prostate cancer risk assessment, FusionVu for MRI-ultrasound alignment and targeting, and Cognitive Assist for cognitive fusion displaying MRI-identified lesions in real time.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Exact Imaging company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Immunicum
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Immunicum
2.2 - Growth funds investing in similar companies to Immunicum
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Immunicum
4.2 - Public trading comparable groups for Immunicum
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →